Program
Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705
Also written as “SSGJ-705” and “SSGJ-705 combined with chemotherapy”.
Its studies are mostly in Neoplasms, led by 3SBio.
Drug pageAnti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Jun 6, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 43 open or running | phase 2since Jun 6, 2025 | Nov 25, 2021 | Dec 2026phase 1 · NCT06390774 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 25, 2021First study: phase 1 study in Receptor, ErbB-2First studyNCT05145179 · 162 enrolled
- Apr 8, 2024Phase 1 study in RecurrenceNCT06390774 · 180 planned · China
- Jun 6, 2025Phase 2 study in RecurrenceNCT07022002 · 340 planned · China
- Jun 8, 2026Phase 2 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT07646626 · 150 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in RecurrenceNCT06390774
- Dec 31, 2026Primary completion: phase 2 study in RecurrenceNCT07022002
- Jun 30, 2027Primary completion: phase 2 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT07646626
TargetBeta
“A bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07646626Locally Advanced (Unresectable) or Metastatic Solid Tumors · China | 2 | Recruiting | Jun 30, 2027 | 150 |
| NCT07022002Recurrence · China | 2 | Recruiting | Dec 31, 2026 | 340 |
| NCT06390774Recurrence · China | 1 | Recruiting | Dec 2026 | 180 |
| NCT05145179Receptor, ErbB-2 | 1 | UNKNOWN | Dec 1, 2023 | 162 |
How it is read
Names in the registry
- “SSGJ-705”, 4 entries
- “SSGJ-705 combined with chemotherapy”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.